Metoject Subcutaneous 22.5 mg

METOJECT SUBCUTANEOUS 22.5 MG is a methotrexate sodium solution designed for subcutaneous use. This medication is commonly used in the management of certain medical conditions, including rheumatoid arthritis and psoriasis. It is manufactured by Medexus Pharmaceuticals Inc. in Canada.

METOJECT SUBCUTANEOUS 22.5 MG is primarily used for the treatment of severe rheumatoid arthritis and psoriasis. It works by reducing inflammation and suppressing the immune system. This medication is often prescribed when other treatments have not been effective. It is important to follow the advice of a healthcare professional regarding its use.

Common effects of METOJECT SUBCUTANEOUS 22.5 MG may include nausea, fatigue, and mild skin irritation at the injection site. Some users may also experience mouth sores or changes in hair growth. These effects vary from person to person and are not experienced by everyone who uses this medication.

METOJECT SUBCUTANEOUS 22.5 MG should be handled with care. It is important to store it properly and use it exactly as directed. Avoid using this medication if you are allergic to methotrexate or any of its components. Always inform your healthcare provider about any other medications you are taking to avoid potential interactions.

METOJECT SUBCUTANEOUS 22.5 MG may interact with certain medications, including nonsteroidal anti-inflammatory drugs (NSAIDs), antibiotics, and other immunosuppressants. Alcohol consumption should be avoided as it can increase the risk of side effects. Always consult a healthcare professional before combining this medication with other treatments.